

NDA 21153-S60
NDA 21957-S27
NDA 22101-S24

SUPPLEMENT APPROVAL

AstraZeneca Pharmaceuticals LP
Attention: Prameela Adapa
Associate Regulatory Affairs Director
One MedImmune Way
Gaithersburg, MD 20878

Dear Ms. Adapa:

Please refer to your supplemental new drug applications (sNDAs), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

Application #	Dated and Received	Drug and Dosage
NDA 21153-S60	June 21, 2023	Nexium (esomeprazole magnesium) delayed-release capsules
NDA 22101-S24	June 21, 2023	Nexium (esomeprazole magnesium) for delayed-release oral suspension, 10 mg
NDA 21957-S27	June 20, 2023	Nexium (esomeprazole magnesium) for delayed-release oral suspension, 20 mg and 40 mg

We also refer to our letter dated April 14, 2023, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we have determined should be included in the labeling for proton pump inhibitor (PPI) products. This information pertains to the risk of erectile dysfunction.

This supplemental new drug application provides for revisions to the labeling for Nexium products, consistent with our April 14, 2023 letter adding erectile dysfunction in section 6.2 Postmarketing Experience.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (Prescribing Information), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

NDA 21153-S60
NDA 21957-S27
NDA 22101-S24
Page 3

If you have any questions, call Jacqueline LeeHoffman, Safety Regulatory Project Manager, at (240) 402-8689.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology (DG)
Office of Immunology and Inflammation (OII)
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide
 - Instructions for Use

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JOYCE A KORVICK
07/18/2023 01:13:49 PM